Effects of Stand-Alone Digital Lifestyle Interventions on Weight-Related Outcomes in Adults With Overweight or Obesity: Systematic Review and Meta-Analysis of Randomized Controlled Trials - Top-Institutions - MDSpire

Effects of Stand-Alone Digital Lifestyle Interventions on Weight-Related Outcomes in Adults With Overweight or Obesity: Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • By

  • Si-An Lee

  • Jin-Hyuck Park

  • May 4, 2026

  • 0 min

Share

Top Institutions in Orthopedic Medicine

Brief introduction explaining scope and methodology.

  • #1

    Northwestern University Feinberg School of Medicine / Northwestern Memorial Hospital
    Northwestern University Feinberg School of Medicine / Northwestern Memorial Hospital

    Chicago, IL

    Key Differentiators

    • Obesity Medicine
    • Public Health

  • #2

    University of Pennsylvania (Perelman School of Medicine) / Hospitals of the University of Pennsylvania–Penn Presbyterian
    University of Pennsylvania (Perelman School of Medicine) / Hospitals of the University of Pennsylvania–Penn Presbyterian

    Philadelphia, PA

    Key Differentiators

    • Obesity Medicine
    • Behavioral Economics

  • #3

    Johns Hopkins Medicine / The Johns Hopkins Hospital
    Johns Hopkins Medicine / The Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Obesity Medicine
    • Preventive Medicine

Original Source(s)

Effects of Stand-Alone Digital Lifestyle Interventions on Weight-Related Outcomes in Adults With Overweight or Obesity: Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • by Si-An Lee, Jin-Hyuck Park

  • May 4, 2026

Related Content

Grip Strength Plus Waist Size May Flag Risk T2D Risk

Researchers found that patients with higher waist circumference and lower grip strength had the greatest risk for developing type 2 diabetes during long-term follow-up.

Case Report: rapid progressive puberty in siblings with MC4R p. Arg165Gln: longitudinal follow-up and gonadotropin-releasing hormone agonist treatment

The Lipitor Warning for GLP-1 Drugmakers

Pfizer’s Lipitor experience shows the structural risks that today’s GLP-1 innovators may soon face